Specialization Over Expansion: Rethinking Injectable Authority for Pharmacists in a Post–COVID-19 Health Care Landscape

The question of whether pharmacists should administer injections beyond vaccines is often framed as a debate about professional scope expansion, but that framing is increasingly outdated. In a post–COVID-19 health care environment defined by access constraints, workforce shortages, and evolving patient expectations, the discussion is no longer about what professions prefer to do but about what the public needs to receive timely, safe care. For patients, this debate directly affects access, safety, and the ability to receive timely care in an increasingly strained health care system.

At its core, this is not a debate about expansion for expansion’s sake. It is a conversation about specialization, public safety, and whether regulatory frameworks designed for a prepandemic health care system still serve the public interest today.

Why Post–COVID-19 Health Care Demands New Approaches to Injectable Authority

It is true that many pharmacists do not wish to administer injections, and that position deserves respect. Community pharmacy practice is already burdened by staffing shortages, workflow compression, and escalating clinical expectations. Mandating universal injectable responsibilities would be counterproductive and risks accelerating professional burnout. However, rejecting injectable authority wholesale because it is undesirable for some pharmacists fails to account for the growing reality that health care access gaps are already being filled—often by individuals operating outside formal regulatory oversight.

The COVID-19 pandemic fundamentally altered how the public accesses care. During the crisis, pharmacists became essential frontline providers, delivering vaccinations, triaging patients, managing medication shortages, and serving populations that could not access traditional medical offices.¹ This shift was not merely convenient; it was necessary. The public learned—correctly—that pharmacists are capable of safely delivering hands-on clinical services when appropriately trained and authorized.

Yet, in the post–COVID-19 era, regulatory thinking in some areas has failed to evolve at the same pace as public need.

This disconnect is particularly evident in the rise of unauthorized individuals administering cosmetic injectables, including neuromodulators such as botulinum toxin products.² Across many jurisdictions, patients are receiving injections in nonclinical settings from individuals with no formal medical training, limited pharmacologic knowledge, and minimal accountability. These practices persist not because they are safe, but because access barriers within the regulated health care system leave patients with few timely alternatives. From a public safety standpoint, this should be deeply concerning.

Unregulated Cosmetic Injectables Highlight Growing Patient Safety Risks

Pharmacists occupy a unique and underutilized position in this landscape. As licensed health care professionals with extensive training in pharmacology, medication safety, contraindication screening, and adverse event recognition, pharmacists are inherently equipped to manage injectable therapies more safely than many unlicensed actors currently operating in the cosmetic space. Despite this, pharmacists remain largely excluded from administering cosmetic injectables—even when acting under physician direction and within controlled environments.³

This exclusion raises an increasingly unavoidable question: Does prohibiting trained pharmacists from administering certain injectables meaningfully protect the public, or does it inadvertently preserve conditions that allow unregulated practice to flourish? In a post–COVID-19 health care system defined by access constraints, the answer matters.

Why Pharmacist-Delivered Injectables Should Be Built on Voluntary Specialization

The solution is not indiscriminate expansion. Injectable authority should not be universal, nor should it be imposed upon pharmacists who do not wish to practice in this capacity. Rather, it should be structured around voluntary specialization, with public safety—not professional convenience—as the guiding principle.

A specialization-based model offers a pragmatic and patient-centered middle ground. Under such a framework, pharmacists who elect to administer select injectable therapies would meet requirements exceeding standard immunization certification. These would include advanced didactic training specific to the injectable class, formal competency assessments, mandatory malpractice coverage, and ongoing continuing education. Participation would be intentional and opt-in, not presumed.

Equally critical is the practice environment. Injectable administration—particularly neuromodulator or cosmetic injections—should not occur at standard retail pharmacy counters. Designated clinical settings, whether embedded within pharmacies or affiliated medical or wellness facilities, would ensure appropriate storage, privacy, emergency preparedness, and regulatory oversight. Such guardrails are not obstacles; they are protections that directly benefit patients.

Limiting authority by injectable class further reinforces safety. The conversation should not revolve around all injectables but around narrowly defined categories with established safety profiles. Neuromodulators, for example, represent a well-studied class distinct from dermal fillers, intravenous therapies, or complex biologics. Precision—not breadth—should guide policy.

Concerns about scope creep and professional identity are valid and deserve thoughtful consideration. Pharmacists are not seeking to replace physicians, nurses, or physician assistants. Rather, the profession is responding to a fragmented, postpandemic health care environment in which unmet demand is routinely met by unregulated alternatives. A regulated, pharmacist-led injectable model does not blur professional boundaries; it reinforces them by anchoring care delivery within licensed, accountable practice.

It is also important to recognize that pharmacists already administer injections in high-stakes contexts. Vaccination programs, emergency naloxone administration, and the more recent authorization to administer long-acting injectable therapies for mental health and substance use disorders demonstrate that pharmacists can safely and effectively perform injectable procedures when appropriately trained and regulated. These precedents underscore that injectable administration is not foreign to pharmacy practice—it is already embedded within it.

Evidence Shows Pharmacists Already Provide Safe, Regulated Injection Services

Ultimately, the question is no longer whether pharmacists should administer injections in the abstract. The more pressing question is whether health care systems and regulators are willing to acknowledge that frameworks designed for a pre–COVID-19 world no longer adequately serve the public.

In an era defined by access gaps and rising demand, expansion of services—when executed through specialization, regulation, and accountability—is not merely beneficial. It is necessary. By allowing qualified pharmacists to administer select injectables under clearly defined requirements and in controlled settings, regulators can enhance public safety, expand access to care, and reduce reliance on unregulated practices without imposing unwanted responsibilities on the broader profession. Access will continue to exist regardless of regulatory posture.

The choice facing policy makers is whether that access is delivered by trained, accountable professionals or left to persist in the shadows of inadequate oversight. In a post–COVID-19 health care environment in which access gaps are no longer hypothetical, maintaining prepandemic regulatory assumptions is no longer neutral—it is a decision with real public consequences.

REFERENCES

1. Visacri MB, Figueiredo IV, Lima TM. Role of pharmacist during the COVID-19 pandemic: a scoping review. Res Social Adm Pharm. 2021;17(1):1799-1806. doi:10.1016/j.sapharm.2020.07.003

2. The dangers of unqualified cosmetic injectors. SkinCare Physicians. Accessed April 13, 2026. https://www.skincarephysicians.net/news-events/press-releases/dangers-of-unqualified-injectors/

3. Oji V, McKoy-Beach Y, Pagan T, Matike B, Akiyode O. Injectable administration privileges among pharmacists in the United States. Am J Health Syst Pharm. 2012;69(22):2002-2005. doi:10.1093/ajhp/69.22.2002